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Summary 
Changing patterns of psychoactive drug injection are increasing risk 
The recent increase in the number of people injecting a range of stimulants, particularly the 
recently emerged psychoactive drugs such as mephedrone, is a concern. Over the past 
decade, the number of people reporting that amphetamines and amphetamine-type drugs are 
their main drug of injection has increased three-fold. One in eight now say these are the main 
drug they inject. People injecting stimulants report higher levels of risk behaviours such as 
sharing and reusing needles and syringes. Although the number injecting these drugs remains 
small when compared to those injecting opiates or image and performance enhancing drugs, 
the higher level of risk behaviours associated with their use can increase harm.  
Bacterial infections continue to be a problem 
A third of people who inject psychoactive drugs report having a recent symptom of a bacterial 
infection. Outbreaks of infections due to bacteria, such as Clostridium botulinum, continue to 
occur in this group. Some of these infections are severe and place substantial demands on 
healthcare. 
Half of those with hepatitis C remain unaware of their status 
Hepatitis C remains a major problem among people who inject drugs in the UK, with significant 
levels of transmission continuing to occur. Two in five of those who inject psychoactive drugs 
are living with hepatitis C and about half of these infections remain undiagnosed. This 
underlines the need to identify, and make use of, the opportunities for regularly offering tests to 
those at risk. 
Hepatitis B remains rare, but vaccine uptake has stopped improving  
Around one in 200 people who have injected psychoactive drugs are living with hepatitis B 
infection. This low level probably reflects the marked increase in the uptake of the hepatitis B 
vaccine. Vaccination uptake in this group is no longer increasing and may now be declining. 
Most of those who have not been vaccinated have been in contact with health services where 
they could have received a dose of the vaccine. 
HIV levels remain low overall and the uptake of care is good 
Only around one in 100 people who inject drugs are living with HIV; most of these people will 
have been diagnosed and be in receipt of care. However, HIV transmission continues among 
people who inject drugs and the recent outbreak in Scotland is a concern. 
Provision of effective interventions needs to be maintained 
The provision of effective interventions, such as needle and syringe programmes, 
opioid substitution therapy and other treatments for drug use, which act to reduce risk 
and prevent infections, need to be maintained. These interventions need to respond to 
any changes in patterns of drug use and associated risk. Vaccinations and diagnostic 
tests for infections need to be routinely and regularly offered to people who inject drugs 
in line with guidance. Appropriate care pathways and treatments should be available to 
those testing positive.
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Introduction 
People who inject drugs are vulnerable to a wide range of viral and bacterial infections. 
These infections can result in high levels of illness and death. Public health surveillance 
of infectious diseases and the associated risk and protective behaviours among this 
group provides important information. This information is essential to understanding the 
extent of these infections, the risk factors for their acquisition, and for monitoring the 
effectiveness of prevention measures.  
 
This annual national report describes trends in the extent of infections and associated 
risks and behaviours among people who inject drugs in the UK to the end of 2014.a 
Further information can be found in the set of data tables that accompany this report.b  
 
Changing patterns of psychoactive drug 
injection are increasing risk 
The types of psychoactive drugs being injected in the UK are continuing to change, 
though heroin remains the most commonly injected psychoactive drug. In part, this 
reflects a decline in the injection of opiates and crack-cocaine in England.1 However, 
the injection of other psychoactive drugs, particularly stimulants such as amphetamines 
and amphetamine-typec drugs, has become more common in recent years. The use of 
stimulants has been associated with higher levels of risk behaviours and lower levels of 
intervention uptake.2 There are concerns about the injection of some of the recently 
emerged psychoactive drugsd, in particular the amphetamine-type stimulant, 
mephedrone. The use of mephedrone was first noted in the UK in 20083 and it was 
controlled under the Misuse of Drugs Act in 2010. Mephedrone injecting is a more 
recent practice which occurs mainly among people who have previously injected other 
drugs, and among people who have switched from snorting mephedrone.4  
 
  
                                            
 
a
 Where data have been previously published, only the proportions are usually given in this report. The numerators and 
denominators for these proportions can be found in the source publications. 
b
 The data tables can be found on this webpage: https://www.gov.uk/government/statistics/people-who-inject-drugs-hiv-and-
viral-hepatitis-monitoring. 
c
 Amphetamine-type drugs include a number of substances with similar properties to amphetamines such as ecstasy and the 
synthetic cathinones including mephedrone. 
d
 Recently emerged psychoactive drugs are those drugs which have become available recently and are not controlled by 
international treaties, such as, mephedrone and ethylphenidate. This term includes a wide range of substances, some of which 
can be injected. Those injected are typically stimulants. 
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Changing nature of injecting 
The proportion of people surveyed in England, Wales and Northern Ireland who report 
injecting amphetamines and amphetamine-type drugs as their main drug rose from 
3.9% (58/1,460) in 2004 to 12% (159/1,354) in 2014; overall, opiates remain the most 
commonly injected main drug (Figure 1). In England, Wales and Northern Ireland, 24% 
of those surveyed in 2014 reported that they had injected amphetamine (‘speed’) during 
the preceding month, an increase from 18% in 2010.5 Mephedrone injection during the 
preceding month was reported by 5.9% (92/1,554) in 2014, with 8.9% (184/2,054) 
having injected this drug at some point during the preceding year. Those who had 
injected mephedrone were younger than those who had not.e 
 
Figure 1: Main drug type injected among those currently* injecting psychoactive drugs 
in England, Wales & Northern Ireland: 2004 to 2014  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Among those who had injected psychoactive drugs during the preceding 28 days. 
Data source: Unlinked Anonymous Monitoring Survey of people who inject drugs. 
 
 
In Scotland, among people who had injected drugs during the past six months, heroin 
was the most commonly injected drug, reported by nine-tenths of those surveyed at 
                                            
 
e
 The mean age of those who reported that they had injected mephedrone was 33 years compared to 37 years for those who 
had not. 
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services providing injecting equipment between 2008 and 2014.f The proportion 
reporting powder cocaine as their main drug of injection remains low, but has increased 
in recent years, up from 2.5% in 2010 to 3.9% in 2013-14. Reports of the use of the 
recently emerged psychoactive drugs are rare but increasing, with 2.5% (49/1,933) of 
respondents reporting recent injection of these drugs in 2013-14, up from 0.1% in 2011-
12.6 Prevalence of recent injection of these drugs in 2013-14 was highest in the Lothian 
Health Board area (9.0%, 22/245).  
 
Data from both England and Wales indicate that there have been changes in the types 
of drugs being injected among those presenting to services that provide treatment for 
drug use, and in particular an increase in presentations reporting the injection of 
amphetamines or amphetamine-type drugs and of the recently emerged psychoactive 
drugs.2,7 The vast majority of those presenting to treatment services are injecting heroin. 
Data from Wales also indicate a similar pattern among those accessing needle and 
syringe programmes, with the proportion of individuals reporting injection of 
amphetamine and amphetamine-type drugs as their main drug increasing from 7% in 
2011-12 to 10% in 2013-14.8  
 
Higher levels of injecting risk 
Overall, the level of needle and syringe sharing (either borrowing or lending a used 
needle or syringe) among those currently injecting psychoactive drugs has fallen across 
the UK. In Scotland, sharing in the previous month fell from 22% during 2006-07 to 14% 
in 2013-14 among individuals attending drug treatment services (Accompanying Data, 
Table 3), while in England, Wales and Northern Ireland sharing fell from 28% in 2004 to 
17% in 2014 (Accompanying Data, Table 3). Those currently injecting mephedrone 
were, however, more likely to report sharing (Figure 2).g  
 
The sharing of filters and mixing containers is more common, and was nearly twice as 
frequent among those injecting mephedrone (Figure 2).h The sharing of mixing 
containers, filters, needles and/or syringes, was reported by nearly two in five (38%) of 
those surveyed across England, Wales and Northern Ireland in 2014 (Accompanying 
Data, Table 3). Those who had injected amphetamine during the preceding month were 
also more likely to report that they had shared injecting equipment, with 43% reporting 
this.i 
                                            
 
f
 Surveys were undertaken in 2008-09, 2010, 2011-12 and 2013-14, with heroin use reported by between 89% to 93%. 
g
 Sharing of needles and syringes was reported by 27% (24/90) of those who reported injecting mephedrone during the 
preceding 28 days compared to 16% (232/1,413) of those who had not.  
h
 Sharing of mixing containers was reported by 53% (48/91) of those who had injected mephedrone during the preceding 28 
days compared to 29% (422/1,452) of those who had not; and the sharing of filters was reported by 47% (43/91) of those who 
had injected mephedrone during the preceding 28 days compared to 26% (232/1,413) of those who had not. 
i
 Sharing of needles, syringes, mixing container and/or filters was reported by 43% (160/369) of those who reported injecting 
amphetamine during the preceding 28 days compared to 37% (430/1,170) of those who had not. 
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Cleaning and reusing injecting equipment also remains common among those injecting 
psychoactive drugs, and again this was more frequent among those injecting 
mephedrone (Figure 2).j Overall in 2014, 29% of those currently injecting psychoactive 
drugs in England, Wales and Northern Ireland reported injecting with a needle that had 
previously been used and which they had then attempted to clean.18   
 
Figure 2: Injecting risk behaviours* among those injecting mephedrone in England, 
Wales & Northern Ireland: 2014  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
 
*Among those who had injected psychoactive drugs during the preceding 28 days. 
Data source: Unlinked Anonymous Monitoring Survey of people who inject drugs. 
 
 
  
                                            
 
j
 Injecting with a needle that had been cleaned before reuse during the preceding 28 days was reported by 42% (38/91) of 
those who had injected mephedrone during the preceding 28 days compared to 28% (404/1,451) of those who had not.  
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Increased harms 
In England, Wales and Northern Ireland, those who reported that they had injected 
mephedrone during the preceding year were more likely to have HIV, to have antibodies 
to hepatitis C virus, and to report having had an injection site infection during the 
preceding year.k These findings suggest that mephedrone injecting may have emerged 
among higher risk groups with already elevated levels of infection. Those who reported 
that they had injected amphetamine during the past year were also more likely to have 
antibodies to hepatitis C than those who had not.l 
 
Increased injection of stimulants has been reported to be a factor in a number of 
outbreaks of injection related infections. In south west Wales, an increase in infections 
and other harms has been associated with the emergence of the injection of synthetic 
cathinones, including mephedrone. The changes in injection practice associated with 
the use of these stimulants probably markedly increased risks (box 1). In the Lothian 
area of Scotland, there has recently been a large outbreak of soft-tissue infections 
among people who inject drugs. Although the people involved had injected a range of 
drugs, they commonly reported that a recently emerged psychoactive drug, believed to 
be ethylphenidate, was among the drugs they had used.9 The use of this relatively short 
acting stimulant is known to increase injection frequency and so increase risks. 
 
There have been increases in HIV transmission among people who inject drugs in a 
number of European countries in recent years that have been associated with the 
emergence of the injection of stimulants, usually in populations already injecting 
opiates.10,11,12 The most recent of these outbreaks in Dublin13 has been linked to the 
injection of a synthetic cathinone.  
 
Overall, these findings indicate an increase in the number of people injecting stimulants, 
particularly amphetamines and amphetamine-type drugs, in the UK. It is worrying that 
within five years of it first appearing, around one-in-ten people who inject drugs reported 
the injection of mephedrone. There are also ongoing concerns about the injection of 
mephedrone and other drugs among some sub-groups of MSM during sex, with 
injecting equipment often shared and condoms not being used.14,15  
                                            
 
k 
Of those who had injected mephedrone during the preceding year: 2.7% (5/184) had HIV compared with 0.7% (13/1,870) of 
those who had not, after adjusting for age, gender/male sexuality, and region of recruitment this difference remains (adjusted 
odds ratio of 4.0, 95%CI 1.3-12); 55% (101/184) had antibodies to hepatitis C compared with 52% (966/1,870) of those who 
had not, after adjusting for age, gender/male sexuality, and region of recruitment this difference remains (adjusted odds ratio of 
1.5, 95%CI 1.1-2.0); and 42% (68/163) reported a symptom of an injecting site infection compared with 30% (489/1,634) of 
those who had not, after adjusting for age, gender/male sexuality, and region of recruitment this difference remains (adjusted 
odds ratio of 1.7, 95%CI 1.2-2.4). 
l
 Of those who had injected amphetamine during the preceding year, 55% (334/609) had antibodies to hepatitis C compared 
with 51% (733/1,445) of those who had not, after adjusting for age, gender/male sexuality, and region of recruitment this 
difference remains (adjusted odds ratio of 1.4, 95%CI 1.1-1.7). There were no differences in the prevalence of HIV or the extent 
of symptoms of injecting site infections. 
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Box 1: Increases in risk behaviours and blood borne virus infection among 
people who inject psychoactive drugs in South Wales 
 
Over the past 18 months, Public Health Wales has identified a sharp rise in new 
hepatitis C diagnoses among people who inject drugs, as well as a small cluster of 
individuals newly diagnosed with HIV and hepatitis C co-infection in south west Wales.  
 
This problem is linked to an historic opioid injecting population starting to inject 
stimulants, specifically some of the psychoactive drugs that have recently emerged. An 
increase in the number of people who mainly inject stimulants has also been seen. 
Injection of the recently emerged stimulant drugs, specifically cathinones such as 
mephedrone, is associated with increased risk behaviours (such as increased injecting 
frequency and sharing of injecting equipment), due to the effects of the drugs leading to 
compulsive use. This increases the risks of transmission of blood borne viruses, as well 
as injection site infections, abscesses and deep vein thrombosis.  
 
Where recorded, the number of individuals accessing specialist needle and syringe 
programmes who self-report injection of a recently emerged psychoactive drug rose by 
168% (from 154 in 2011-12 to 412 in 2014-15). Over the same period, survey data 
indicate that the prevalence of hepatitis C infection has increased from 39% to 50%. 
 
In response, Public Health Wales is currently revising the surveillance systems for blood 
borne virus infection among people who inject drugs; developing proactive community 
outreach for those not in contact with any services including needle and syringe 
programmes; increasing the accessibility and provision of sterile injecting equipment; 
increasing the opportunity for blood borne virus testing in specialist services and in a 
range of community environments; and, raising awareness, particularly in relation to co-
infection with HIV.   
 
Bacterial infections continue to be a 
problem 
Almost a third (31%) of those injecting psychoactive drugs in England, Wales and 
Northern Ireland in 2014 reported that they had experienced an abscess, sore or open 
wound (all possible symptoms of an injecting site infection) during the past year 
(Accompanying Data, Table 2). This compares to 35% in 2006. These symptoms are 
more commonly reported by women (37%) than men (29%).5 Among those attending 
needle and syringe programmes in Scotland during 2013-14, 28% reported that they 
had experienced an abscess, sore or open wound, during the past year. These 
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infections are also an issue among people injecting image and performance enhancing 
drugs, such as anabolic steroids, peptides and melanotan, with 16% of this group 
reporting that they have ever had an abscess, sore or open wound in 2012-13.19 
 
Illnesses, such as botulism, which are caused by the toxins produced by a number of 
spore-forming bacteria, continue to cause problems among people who inject drugs. 
The spores produced by these bacteria are found in the environment, and may end up 
in drugs, such as heroin, through contamination. Between 2000 and 2013, there had 
been a total 167 cases of botulism among people who inject drugs in the UK. During 
2014 there were a further three cases; the last two of these were the first cases in the 
largest cluster of botulism among people who inject drugs seen in Europe. This cluster, 
centered on Glasgow, involved a total of 40 cases over a six-month period (box 2). 
There were no cases of tetanus or anthrax among people who inject drugs in the UK 
during 2014 (Accompanying Data, Table 2). 
 
Severe illnesses among people who inject drugs due to hygiene related bacterial 
infections, including those caused by Staphylococcus aureus and Group A streptococci, 
continue to occur (Accompanying Data, Table 2). Data from the mandatory enhanced 
surveillance of meticillin-sensitive S. aureus (MSSA) and meticillin-resistant S. aureus 
(MRSA) bacteraemias indicate that in 2014, of those with risk factor information, 9.2% 
(255/2,772) of the MSSA bacteraemias were associated with injecting drug use, as 
were 4.7% (10/215) of the MRSA bacteraemias (Accompanying Data, Table 2). There 
has recently been a large outbreak of soft tissue infections among people who inject 
psychoactive drugs in Edinburgh, with many of the cases requiring prolonged hospital 
admissions and extensive surgical interventions. Though a number of different 
organisms were detected, Group A streptococci infections, and in particular one less 
commonly seen type of S. pyogenes, were often detected in the cases.9  
 
These data indicate that bacterial infections remain common among people who inject 
drugs, and that outbreaks of infections due to bacteria continue to occur in this group.9 
These infections have a substantive impact on health services,16 with studies indicating 
that around one in 10 people who inject drugs are admitted to hospital each year due to 
a bacterial infection.17 This impact is probably compounded by delays in seeking 
healthcare in response to the initial symptoms of these infections.17 Many of these 
infections could be prevented by reducing risky injecting practices, such as the reuse of 
injecting equipment, and the more serious consequences reduced by prompt treatment. 
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Box 2: Wound botulism cluster in Glasgow: 2014-15 
 
Wound botulism is a rare but potentially fatal illness. It is caused by the powerful 
neurotoxin produced by the bacterium Clostridium botulinum when it grows in damaged 
tissues. The toxin causes paralysis and respiratory problems that can lead to death.   
 
Between December 2014 and May 2015, 40 people who inject drugs were clinically 
diagnosed with botulism. All cases were resident in Scotland, and had injected heroin 
sourced from Glasgow. The majority of cases (98%) presented with bulbar palsy (a form 
of paralysis that affects the muscles in the head); over half (58%) were ventilated for 
respiratory paralysis, although most did not require long-term support. All cases were 
promptly treated with antitoxin, half had wounds cleaned out (debridement) and all 
received antibiotics. There were four deaths; botulism was a contributory cause in two 
of these cases. Seventeen (42%) cases were confirmed by detection of the toxin in 
blood or detection of Clostridium botulinum type B in wound material. Molecular typing 
was undertaken on the organisms isolated from 14 of the cases, and found all these to 
be of the same type, suggesting a common source. 
 
Awareness-raising materials, highlighting the symptoms of botulism, were distributed 
widely among people who use drugs, healthcare professionals, and frontline workers in 
addiction and injecting equipment provision services. A harm minimisation approach 
was taken, advising users to make sure they injected their drugs into a vein, smoked 
drugs as an alternative to injecting, or if possible stopped use altogether. 
 
Botulism health warning ‘postcard’ distributed to people who use drugs 
 
 
 
 
 
 
 
 
 
 
Source: Scottish Drugs Forum (www.sdf.org.uk) / NHS Greater Glasgow and Clyde 
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Half of those with hepatitis C remain 
unaware of their status 
People who inject drugs are the group most affected by hepatitis C in the UK. Around 
90% of the hepatitis C infections diagnosed in the UK will have been acquired through 
injecting drug use. Across the UK, 14,149 positive test results for hepatitis C were 
reported during 2014 (Accompanying Data, Table 1a), though around half of infections 
among people who inject drugs still remain undiagnosed.18 
 
The uptake of voluntary confidential testing for hepatitis C among people injecting 
psychoactive drugs in England, Wales and Northern Ireland increased between 2004 
(67%) and 2010 (82%) (Figure 3a; Accompanying Data, Table 3). However, since then 
the level of uptake has been stable, and in 2014, it was 83% in England, 85% in Wales, 
and 88% in Northern Ireland.5,18  
 
Figure 3. Uptake of the voluntary confidential testing for hepatitis C among people who 
inject drugs: a) England, Wales and Northern Ireland, and b) Scotland  
 
   a) England, Wales and Northern Ireland      b) Scotland 
 
Data source: Unlinked Anonymous Monitoring survey of people who inject drugs (England, 
Wales and Northern Ireland) and Needle Exchange Surveillance Initiative (Scotland). 
 
Data from the National Drug Treatment Monitoring System (NDTMS) indicates that 
levels of hepatitis C testing among people who have ever injected drugs and who are in 
treatment for their drug use have risen in England (Accompanying Data, Table 3). In 
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2013/14, of those who have ever injected drugs, almost nine-tenths (87%) were offered 
a hepatitis C test at the beginning of their most recent treatment period, and of those 
offered, two-thirds (67%) accepted that offer. This indicates that two-fifths (40%) were 
not tested because testing was either not offered or declined.18 About the same 
proportion of those newly presenting to treatment were offered testing (81%), and of 
those offered 58% accepted, indicating more than half (52%) were not tested.18 
 
In 2014, among those injecting psychoactive drugs in England, Wales and Northern 
Ireland, only half (52%) of those with hepatitis C reported that they were aware of their 
hepatitis C status.5 This proportion has remained relatively stable over the past 
decade.5 Of those who were unaware of their positive status, 23% reported never 
having had a test for hepatitis C; and of those unaware but tested, 43% reported that 
their last test had been more than two years ago.m This indicates a need for 
interventions to support regular testing uptake among people who inject drugs (box 3). 
Among those who were unaware of their hepatitis C status, 64% (399/619) had used a 
needle and syringe programme and 70% (430/615) were currently receiving a 
prescribed substitute drug. Many also reported using other health services during the 
preceding year where they could have been tested for hepatitis C: 65% (401/619) had 
seen a general practitioner; 24% (151/619) had attended an emergency department; 
17% (106/619) had used a walk-in/minor injury clinic; and 8.9% (55/619) had attended a 
genitourinary medicine clinic. These data show that those with undiagnosed hepatitis C 
infection make extensive use of specialist services for people who inject drugs and 
primary care, and indicate that there are missed opportunities for hepatitis C testing in 
these settings. 
 
Among those attending needle and syringe programmes in Scotland during 2013-14, 
88% reported having ever been tested for hepatitis C (Accompanying Data, Table 3); 
this is higher than the 74% reported by those surveyed in 2008-09 (Figure 3b). 
 
UK-wide data indicate that around half of those who inject psychoactive drugs have 
been infected with hepatitis C: with 58% of those surveyed in Scotland during 2013-14 
having antibodies to hepatitis C, 50% in England, 50% in Wales, and 23% in Northern 
Ireland18 (Accompanying Data, Table 1a). As around one quarter of those infected with 
hepatitis C naturally clear their infection, these data suggest that about two in five of 
those who inject psychoactive drugs are currently living with hepatitis C infection in the 
UK. 
 
The level of hepatitis C transmission among people who inject psychoactive drugs in the 
UK appears to have shown little change in recent years. In England, Wales and 
                                            
 
m
 Of those participants in the UAM Survey of PWID who had antibodies detected in the biological sample and who did not 
report being aware of their hepatitis C status, 140 out of 619 reported never having had a voluntary confidential diagnostic test 
for hepatitis C. Of those who had been tested, 156 out of 364 reported that their last test was prior to 2013. 
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Northern Ireland, 19% of recent initiates to injecting had been infected in 2014 – this is 
similar to the level found a decade ago (Accompanying Data, Table 1a).n Incidence is 
currently estimated at five to 16 infections per 100 person years of exposure.18 In 
Scotland, hepatitis C incidence among those who inject psychoactive drugs was 
estimated to be 10 infections per 100 person years of exposure during 2013-14.18 
 
Box 3: Hepatitis C improving testing uptake: a case study 
 
Barnet Drug and Alcohol Service undertook a renewed approach to blood borne virus 
testing in the borough. A blood borne virus nurse helped to improve the interventions 
offered to service users. Information about the referral pathways for those wanting a test 
or with a blood borne virus diagnosis were written up, presented and distributed to all 
staff in local drug and alcohol services. The issue of blood borne viruses was regularly 
talked about in team meetings to raise awareness among staff. Staff were also 
encouraged to do the RCGP/PHE course on Hepatitis C: Enhancing Preventing, Testing 
and Care*. 
 
All clients with outstanding blood borne virus interventions were written to and invited for 
hepatitis B, hepatitis C and/or HIV testing, vaccination and appropriate referral for 
treatment for those with positive results. Follow-up letters were sent to those who did 
not initially respond and the nurse also spent time in waiting rooms and in services to 
engage with people, in person. The blood borne virus clinic times were flexible and 
offered on a drop-in basis to help with engagement. All staff have now been trained to 
carry out dried blood spot (DBS) testing so that clients can be routinely and regularly 
offered testing during their key working sessions.  
 
The re-offer of testing to all clients resulted in 266 service users being tested between 
February and August 2015. Of these, 50 tested positive for one or more of hepatitis C, 
hepatitis B or HIV; around four-fifths of those with at least one positive result had 
hepatitis C. Clients have since been referred to appropriate hepatology services and are 
being supported within drug services by a new Wellbeing Clinic set up by the blood 
borne virus nurse to support physical and other health issues. 
 
* www.elearning.rcgp.org.uk/hepc 
 
In England and Wales, among those who only inject image and performance enhancing 
drugs, 3.6% had antibodies to hepatitis C in 2012-13.19 This is lower than the 
prevalence among those who inject psychoactive drugs, but higher than the level in the 
general population (which is around 0.4% in England18). Only 32% of those injecting 
image and performance enhancing drugs reported ever being tested for hepatitis C.19   
                                            
 
n
 A recent initiate is someone who had first injected drugs during the preceding three years. 
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In Scotland, among those who had only injected image and performance drugs during 
the last six months, 5.1% had antibodies to hepatitis C in 2013-14. Just under a third 
(29%) of those injecting image and performance enhancing drugs only in 2013-14 
reported ever being tested for hepatitis C, up from 18% in 2010. 
 
These data show that hepatitis C remains a major problem among people who inject 
drugs in the UK, with high levels of transmission. Although the uptake of testing is high, 
about half of the hepatitis C infections among people who inject drugs remain 
undiagnosed either because they have not been tested, or have become infected since 
their last test. Interventions to reduce the transmission of hepatitis C, diagnostic testing 
services and care pathways for those infected need to be continued and where 
appropriate expanded.18 
 
 
Hepatitis B remains rare, but vaccine 
uptake has stopped improving 
The transmission of hepatitis B continues among people who inject drugs, but it has 
probably declined in recent years. The proportion of people who inject psychoactive 
drugs ever infected with hepatitis B in England, Wales and Northern Ireland has halved 
over the past 10 years, falling from 28% in 2004 to 14% in 2014 (Accompanying Data, 
Table 1b). In 2014, only 0.58% had a current hepatitis B infection, which is similar to the 
level seen in recent years. This suggests that only around one in 200 of people who 
have injected psychoactive drugs are currently living with hepatitis B infection.20  
 
In England, Wales and Northern Ireland, reported uptake of the hepatitis B vaccine (ie 
receiving at least one dose) increased from around half in 2004 to almost three-quarters 
in 2014. However, the level of uptake has declined slightly in recent years (Figure 4a), 
from 76% in 2011 and 72% in 20145,20 (Accompanying Data, Table 3). In 2013, reported 
uptake in England was 72%, in Wales 76%, and in Northern Ireland 78%. Among those 
surveyed in 2014 that had never been infected with hepatitis B and who had taken-up 
vaccination, 61% (1,060/1,742) reported that they had received three or more doses of 
the vaccine and were therefore likely to be fully protected. Of those that had not taken-
up vaccination, 54% (214/397) had recently used a needle and syringe programme and 
55% (219/396) were currently receiving a prescribed substitute drug. A range of other 
health services, where vaccination could have been offered, had been used by this 
group during the preceding year: 62% (247/397) had seen a general practitioner; 26% 
(103/397) had attended an emergency department; 14% (56/397) had used a walk-
in/minor injury clinic; and 7.8% (31/397) had attended a genitourinary medicine clinic. 
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Among those attending needle and syringe programmes in Scotland during 2013-14, 
74% reported uptake of the hepatitis B vaccine (Accompanying Data, Table 3, Figure 
4b). 
 
Figure 4. Uptake of the vaccine against hepatitis B among people who inject drugs: a) 
England, Wales and Northern Ireland, and b) Scotland  
 
   a) England, Wales and Northern Ireland      b) Scotland 
 
Data source: Unlinked Anonymous Monitoring survey of people who inject drugs (England, 
Wales and Northern Ireland) and Needle Exchange Surveillance Initiative (Scotland). 
 
Data from the NDTMS in England indicate that the vast majority of those who have ever 
injected drugs at risk of hepatitis B are offered vaccination against hepatitis B when they 
presented for treatment for their drug use. However, the proportion accepting that offer 
has declined from 61% in 2009/10 to 54% in 2013/14 (Accompanying Data, Table 3). In 
2013/14, more than four-fifths (92%) of this group were offered hepatitis B vaccination 
at the beginning of their most recent treatment period. Of those offered vaccination, 
38% declined, which is an increase on the 26% who declined an offer in 2009/10.  
 
Among people injecting image and performance enhancing drugs in England and 
Wales, 2.8% of them had ever been infected with hepatitis B in 2012-13.3 This is lower 
than among those injecting psychoactive drugs, but probably higher than the level found 
in the general population.21 Only 40% of those injecting image and performance 
enhancing drugs reported uptake of the vaccine against hepatitis B.3 
 
Hepatitis B vaccination uptake in those injecting psychoactive drugs is no longer 
increasing and may now be declining. Even though findings indicate that hepatitis B 
infection among this group is now rare, it is essential that high vaccination levels are 
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maintained. Most of those who have not taken up vaccination have been in contact with 
a number of health services where vaccination could have been provided. This shows 
that there are missed opportunities for vaccination, particularly in specialised drug 
services and primary care, and indicates that local areas need to review vaccination 
provision. There are much lower levels of vaccine uptake among people who inject 
image and performance enhancing drugs; this is a concern and appropriate 
interventions are needed for this group. 
 
HIV levels remain low overall and the 
uptake of care is good 
There were 131 new HIV diagnoses associated with injecting drug use in 2014 
(Accompanying Data, Table 1c). HIV prevalence among those who have ever injected 
psychoactive drugs appears to be stable (Accompanying Data, Table 1c). In England, 
Wales and Northern Ireland, 1.0% of the people who inject psychoactive drugs 
surveyed in 2014 were infected. Among those attending needle and syringe 
programmes in Scotland during 2013-14, 0.8% were HIV antibody positive. The HIV 
prevalence among people who inject drugs in the UK is low compared to many other 
European countries.22  Data indicate that overall HIV incidence among people who 
inject drugs is currently low; very few infections are found among recent initiates to 
injection (Accompanying Data, Table 1c). 
 
Though HIV prevalence is low among people who inject drugs in the UK, outbreaks do 
occur. An outbreak of HIV among people who inject drugs in Glasgow is currently being 
investigated. Glasgow typically records about 10 new diagnoses of HIV associated with 
injecting drug use each year; at the end of August, 36 new diagnoses with this risk had 
already been reported for 2015, nearly all with subtype-C virus. Data indicate that this 
increase in diagnoses is related to transmission among a small, but appreciable 
population of highly chaotic, vulnerable and often homeless people who inject 
psychoactive drugs, mainly heroin. This outbreak is being managed through increasing 
awareness of the risks of HIV, making HIV testing more accessible and proactively 
supporting the early treatment of those newly diagnosed to reduce the risk of onward 
transmission.  
 
Most of those who inject psychoactive drugs reported ever being tested for HIV (77% in 
2014 in England, Wales and Northern Ireland, and 78% in Scotland) and the majority of 
those with HIV were aware of their infection.23 
 
The prevalence of HIV infection among those who inject image and performance 
enhancing drugs was 2.0% in 2012-13. This is similar to the prevalence among people 
who inject psychoactive drugs (after excluding men who report sex with other men – 
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who are at particular risk of HIV through sexual transmission – prevalence was 0.9%).19 
Only 41% of those injecting image and performance enhancing drugs reported ever 
being tested for HIV in 2012-13.19 
 
Owing to improved survival, the number of HIV-infected people seen for HIV treatment 
and care in the UK who had acquired their infection through injecting has increased 
over the past decade, with 1,654 seen in 2014 (Accompanying Data, Table 1c). In 2014, 
418 people who acquired their HIV infection through injecting and who were seen for 
care had CD4 counts of 350 cells/mm3 (the recommended level to start anti-retroviral 
therapy in 2014) or less. Among those seen for HIV treatment and care with CD4 counts 
of 350 or less in 2014, 87% of those who had acquired their infection through injecting 
were on anti-retroviral therapy (Accompanying Data, Table 1c). Following a recent 
revision to the guidelines, anti-retroviral treatment is now recommended for all those 
with HIV.24 In 2014, 90% of those seen for care who had acquired their HIV infection 
through injecting were on anti-retroviral therapy. 
 
Although HIV infections continue to occur among people who inject drugs, these 
findings indicate that the overall HIV prevalence in this group remains comparatively 
low. Most of those with HIV are aware of their infection and uptake of treatment and 
care for HIV among those diagnosed is high. However, the recent HIV outbreak in 
Scotland is a concern. 
 
 
Provision of effective interventions needs to 
be maintained 
Injecting risk behaviours and infections remain common among people who inject 
drugs. The provision of interventions that aim to prevent infections among this group, 
such as needle and syringe programmes and opioid substitution treatment, need to be 
sustained. As the impact of these interventions is dependent on their coverage,25 it is 
important that the level of their provision is regularly reviewed to ensure that it is 
adequate to prevent infections. Ensuring good intervention coverage among those who 
have very recently started to inject is particularly important, as the extent of hepatitis C 
infection in this group indicates that many people are becoming infected soon after they 
start injecting. 
 
Those who commission services to reduce the harm associated with injecting drug use 
should give appropriate priority to preventing the spread of infections. National drug 
strategies acknowledge that tackling drug-related harm and reducing infections are 
important components of a recovery-focused response to drug use.26,27,28,29 Services 
commissioned in line with these strategies, relevant action plans,30,31,32,33 related 
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guidance,34,35,36,37,38,39 and local needs assessments40 should include locally appropriate 
provision of:  
 needle and syringe programmes,  
 opioid substitution treatment  
 other drug treatments 
 
These, and other services such as primary care and sexual health services, should 
provide information and advice on safer injecting practices, preventing infections and 
the safe disposal of used equipment, as well as access to an appropriate range of other 
interventions to reduce injection-related harm. 
 
The changing patterns of psychoactive drug injection are increasing risk as a 
result of the injection of stimulants — particularly amphetamines and amphetamine-type 
drugs — becoming more common. Services that are provided to reduce the risk of 
infections should reflect the increasing range of drugs that are now being injected. 
These services should also be appropriate to the needs of particular groups of people 
who may inject drugs, such as some men who have sex with men. 
 
As bacterial infections continue to be a problem, information and advice on safer 
injecting practices and avoiding injection site infections are important, as are the 
provision of health checks, treatment for injection site infections and tetanus vaccination 
when appropriate.43 
 
Diagnostic testing for hepatitis C is particularly important because among people who 
inject drugs half of those with hepatitis C remain unaware of their status. Well-
designed and supportive care pathways for those infected are also needed. Approaches 
to improve the offer and uptake of hepatitis C testing should be explored. Those who 
continue to inject and are diagnosed with HCV, should have access to effective 
treatment and care, in line with current guidelines.36,41,42 
 
Hepatitis B remains rare, but vaccine uptake has stopped improving, therefore 
provision of vaccination should be maintained in line with guidance43 and ways of 
further improving uptake among people who inject drugs should be explored. The use of 
innovative approaches to reduce the number of missed opportunities for vaccination, 
such as contingency management including the use of incentives,44 should be 
considered. 
 
HIV transmission continues among people who inject drugs in the UK and outbreaks still 
occur. It is therefore important that access to diagnostic testing for HIV and care 
pathways for those infected are maintained to ensure HIV levels remain low overall 
and the uptake of care is good.  
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Injecting risk behaviours, though less common than a decade ago, are continuing to put 
people at risk of infection. A range of easily accessible needle and syringe programmes 
for all people who inject drugs, including those injecting image and performance 
enhancing drugs or using drug treatment services, need to be provided in line with 
guidance.35,39 These programmes should aim to distribute appropriate and sufficient 
injecting-related equipment to prevent sharing and to support hygienic injecting 
practices. They should also offer interventions that support entry into treatment and 
other interventions to decrease or stop injecting (including providing foil45,46). 
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